Chitosan-based nanoformulated (–)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis
Jean Christopher Chamcheu,1,2,* Imtiaz A Siddiqui,1,* Vaqar M Adhami,1,* Stephane Esnault,3 Dhruba J Bharali,4 Abiola S Babatunde,1,5 Stephanie Adame,1 Randall J Massey,6 Gary S Wood,1 B Jack Longley,1 Shaker A Mousa,4 Hasan Mukhtar11Department of Dermatology, School of Medicine and Public...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/53eec2a944e449b39137010fdacb57e5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:53eec2a944e449b39137010fdacb57e5 |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Chitosan nanoparticles topical delivery of chitosan nanoformulated EGCG psoriasis-like skin inflammation phytochemical treatment of psoriasis normal human epidermal keratinocytes differentiation anti-inflammatory action. Medicine (General) R5-920 |
| spellingShingle |
Chitosan nanoparticles topical delivery of chitosan nanoformulated EGCG psoriasis-like skin inflammation phytochemical treatment of psoriasis normal human epidermal keratinocytes differentiation anti-inflammatory action. Medicine (General) R5-920 Chamcheu JC Siddiqui IA Adhami VM Esnault S Bharali DJ Babatunde AS Adame S Massey RJ Wood GS Longley BJ Mousa SA Mukhtar H Chitosan-based nanoformulated (–)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis |
| description |
Jean Christopher Chamcheu,1,2,* Imtiaz A Siddiqui,1,* Vaqar M Adhami,1,* Stephane Esnault,3 Dhruba J Bharali,4 Abiola S Babatunde,1,5 Stephanie Adame,1 Randall J Massey,6 Gary S Wood,1 B Jack Longley,1 Shaker A Mousa,4 Hasan Mukhtar11Department of Dermatology, School of Medicine and Public Health, University of Wisconsin, and the Middleton VA Medical Center, Madison, WI, USA; 2Department of Basic Pharmaceutical Sciences, School of Pharmacy, College of Health and Pharmaceutic Sciences, University of Louisiana at Monroe, Monroe, LA, USA; 3Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, The University of Wisconsin–Madison School of Medicine and Public Health, Madison, WI, USA; 4The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 5Department of Hematology, University of Ilorin, Ilorin, Nigeria; 6Electron Microscope Facility, Medical School Research Support Progs, School of Medicine and Public Health, University of Wisconsin, and the Middleton VAMedical Center, Madison, WI, USA *These authors contributed equally to this work Background: Psoriasis is a chronic and currently incurable inflammatory skin disease characterized by hyperproliferation, aberrant differentiation, and inflammation, leading to disrupted skin barrier function. The use of natural agents that can abrogate these effects could be useful for the treatment of psoriasis. Earlier studies have shown that treatment of keratinocytes and mouse skin with the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) mitigated inflammation and increased the expression of caspase-14 while promoting epidermal differentiation and cornification. However, bioavailability issues have restricted the development of EGCG for the treatment of psoriasis.Materials and methods: To overcome these limitations, we employed a chitosan-based polymeric nanoparticle formulation of EGCG (CHI-EGCG-NPs, hereafter termed nanoEGCG) suitable for topical delivery for treating psoriasis. We investigated and compared the efficacy of nanoEGCG versus native or free EGCG in vitro and in an in vivo imiquimod (IMQ)-induced murine psoriasis-like dermatitis model. The in vivo relevance and efficacy of nanoEGCG formulation (48 µg/mouse) were assessed in an IMQ-induced mouse psoriasis-like skin lesion model compared to free EGCG (1 mg/mouse).Results: Like free EGCG, nanoEGCG treatment induced differentiation, and decreased proliferation and inflammatory responses in cultured keratinocytes, but with a 4-fold dose advantage. Topically applied nanoEGCG elicited a significant (p<0.01) amelioration of psoriasiform pathological markers in IMQ-induced mouse skin lesions, including reductions in ear and skin thickness, erythema and scales, proliferation (Ki-67), infiltratory immune cells (mast cells, neutrophils, macrophages, and CD4+ T cells), and angiogenesis (CD31). We also observed increases in the protein expression of caspase-14, early (keratin-10) and late (filaggrin and loricrin) markers of differentiation, and the activator protein-1 factor (JunB). Importantly, a significant modulation of several psoriasis-related inflammatory cytokines and chemokines was observed compared to the high dose of free EGCG (p<0.05). Taken together, topically applied nanoEGCG displayed a >20-fold dose advantage over free EGCG.Conclusion: Based on these observations, our nanoEGCG formulation represents a promising drug-delivery strategy for treating psoriasis and possibly other inflammatory skin diseases. Keywords: chitosan nanoparticles, topical delivery of chitosan nanoformulated EGCG, psoriasis-like skin inflammation, phytochemical treatment of psoriasis, normal human epidermal keratinocytes, differentiation, anti-inflammatory action |
| format |
article |
| author |
Chamcheu JC Siddiqui IA Adhami VM Esnault S Bharali DJ Babatunde AS Adame S Massey RJ Wood GS Longley BJ Mousa SA Mukhtar H |
| author_facet |
Chamcheu JC Siddiqui IA Adhami VM Esnault S Bharali DJ Babatunde AS Adame S Massey RJ Wood GS Longley BJ Mousa SA Mukhtar H |
| author_sort |
Chamcheu JC |
| title |
Chitosan-based nanoformulated (–)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis |
| title_short |
Chitosan-based nanoformulated (–)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis |
| title_full |
Chitosan-based nanoformulated (–)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis |
| title_fullStr |
Chitosan-based nanoformulated (–)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis |
| title_full_unstemmed |
Chitosan-based nanoformulated (–)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis |
| title_sort |
chitosan-based nanoformulated (–)-epigallocatechin-3-gallate (egcg) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis |
| publisher |
Dove Medical Press |
| publishDate |
2018 |
| url |
https://doaj.org/article/53eec2a944e449b39137010fdacb57e5 |
| work_keys_str_mv |
AT chamcheujc chitosanbasednanoformulatedndashepigallocatechin3gallateegcgmodulateshumankeratinocyteinducedresponsesandalleviatesimiquimodinducedmurinepsoriasiformdermatitis AT siddiquiia chitosanbasednanoformulatedndashepigallocatechin3gallateegcgmodulateshumankeratinocyteinducedresponsesandalleviatesimiquimodinducedmurinepsoriasiformdermatitis AT adhamivm chitosanbasednanoformulatedndashepigallocatechin3gallateegcgmodulateshumankeratinocyteinducedresponsesandalleviatesimiquimodinducedmurinepsoriasiformdermatitis AT esnaults chitosanbasednanoformulatedndashepigallocatechin3gallateegcgmodulateshumankeratinocyteinducedresponsesandalleviatesimiquimodinducedmurinepsoriasiformdermatitis AT bharalidj chitosanbasednanoformulatedndashepigallocatechin3gallateegcgmodulateshumankeratinocyteinducedresponsesandalleviatesimiquimodinducedmurinepsoriasiformdermatitis AT babatundeas chitosanbasednanoformulatedndashepigallocatechin3gallateegcgmodulateshumankeratinocyteinducedresponsesandalleviatesimiquimodinducedmurinepsoriasiformdermatitis AT adames chitosanbasednanoformulatedndashepigallocatechin3gallateegcgmodulateshumankeratinocyteinducedresponsesandalleviatesimiquimodinducedmurinepsoriasiformdermatitis AT masseyrj chitosanbasednanoformulatedndashepigallocatechin3gallateegcgmodulateshumankeratinocyteinducedresponsesandalleviatesimiquimodinducedmurinepsoriasiformdermatitis AT woodgs chitosanbasednanoformulatedndashepigallocatechin3gallateegcgmodulateshumankeratinocyteinducedresponsesandalleviatesimiquimodinducedmurinepsoriasiformdermatitis AT longleybj chitosanbasednanoformulatedndashepigallocatechin3gallateegcgmodulateshumankeratinocyteinducedresponsesandalleviatesimiquimodinducedmurinepsoriasiformdermatitis AT mousasa chitosanbasednanoformulatedndashepigallocatechin3gallateegcgmodulateshumankeratinocyteinducedresponsesandalleviatesimiquimodinducedmurinepsoriasiformdermatitis AT mukhtarh chitosanbasednanoformulatedndashepigallocatechin3gallateegcgmodulateshumankeratinocyteinducedresponsesandalleviatesimiquimodinducedmurinepsoriasiformdermatitis |
| _version_ |
1718401366141960192 |
| spelling |
oai:doaj.org-article:53eec2a944e449b39137010fdacb57e52021-12-02T04:14:08ZChitosan-based nanoformulated (–)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis1178-2013https://doaj.org/article/53eec2a944e449b39137010fdacb57e52018-07-01T00:00:00Zhttps://www.dovepress.com/chitosan-based-nanoformulated-epigallocatechin-3-gallate-egcg-modulate-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Jean Christopher Chamcheu,1,2,* Imtiaz A Siddiqui,1,* Vaqar M Adhami,1,* Stephane Esnault,3 Dhruba J Bharali,4 Abiola S Babatunde,1,5 Stephanie Adame,1 Randall J Massey,6 Gary S Wood,1 B Jack Longley,1 Shaker A Mousa,4 Hasan Mukhtar11Department of Dermatology, School of Medicine and Public Health, University of Wisconsin, and the Middleton VA Medical Center, Madison, WI, USA; 2Department of Basic Pharmaceutical Sciences, School of Pharmacy, College of Health and Pharmaceutic Sciences, University of Louisiana at Monroe, Monroe, LA, USA; 3Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, The University of Wisconsin–Madison School of Medicine and Public Health, Madison, WI, USA; 4The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 5Department of Hematology, University of Ilorin, Ilorin, Nigeria; 6Electron Microscope Facility, Medical School Research Support Progs, School of Medicine and Public Health, University of Wisconsin, and the Middleton VAMedical Center, Madison, WI, USA *These authors contributed equally to this work Background: Psoriasis is a chronic and currently incurable inflammatory skin disease characterized by hyperproliferation, aberrant differentiation, and inflammation, leading to disrupted skin barrier function. The use of natural agents that can abrogate these effects could be useful for the treatment of psoriasis. Earlier studies have shown that treatment of keratinocytes and mouse skin with the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) mitigated inflammation and increased the expression of caspase-14 while promoting epidermal differentiation and cornification. However, bioavailability issues have restricted the development of EGCG for the treatment of psoriasis.Materials and methods: To overcome these limitations, we employed a chitosan-based polymeric nanoparticle formulation of EGCG (CHI-EGCG-NPs, hereafter termed nanoEGCG) suitable for topical delivery for treating psoriasis. We investigated and compared the efficacy of nanoEGCG versus native or free EGCG in vitro and in an in vivo imiquimod (IMQ)-induced murine psoriasis-like dermatitis model. The in vivo relevance and efficacy of nanoEGCG formulation (48 µg/mouse) were assessed in an IMQ-induced mouse psoriasis-like skin lesion model compared to free EGCG (1 mg/mouse).Results: Like free EGCG, nanoEGCG treatment induced differentiation, and decreased proliferation and inflammatory responses in cultured keratinocytes, but with a 4-fold dose advantage. Topically applied nanoEGCG elicited a significant (p<0.01) amelioration of psoriasiform pathological markers in IMQ-induced mouse skin lesions, including reductions in ear and skin thickness, erythema and scales, proliferation (Ki-67), infiltratory immune cells (mast cells, neutrophils, macrophages, and CD4+ T cells), and angiogenesis (CD31). We also observed increases in the protein expression of caspase-14, early (keratin-10) and late (filaggrin and loricrin) markers of differentiation, and the activator protein-1 factor (JunB). Importantly, a significant modulation of several psoriasis-related inflammatory cytokines and chemokines was observed compared to the high dose of free EGCG (p<0.05). Taken together, topically applied nanoEGCG displayed a >20-fold dose advantage over free EGCG.Conclusion: Based on these observations, our nanoEGCG formulation represents a promising drug-delivery strategy for treating psoriasis and possibly other inflammatory skin diseases. Keywords: chitosan nanoparticles, topical delivery of chitosan nanoformulated EGCG, psoriasis-like skin inflammation, phytochemical treatment of psoriasis, normal human epidermal keratinocytes, differentiation, anti-inflammatory actionChamcheu JCSiddiqui IAAdhami VMEsnault SBharali DJBabatunde ASAdame SMassey RJWood GSLongley BJMousa SAMukhtar HDove Medical PressarticleChitosan nanoparticlestopical delivery of chitosan nanoformulated EGCGpsoriasis-like skin inflammationphytochemical treatment of psoriasisnormal human epidermal keratinocytesdifferentiationanti-inflammatory action.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 4189-4206 (2018) |